Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
Oncology Letters|November 8, 2024
Importance of driver gene mutation assessment and targeted therapy for patients with early‑stage non‑small cell lung cancer and non‑R0 resectionPei-Yi Shen, Cheng-Yen Chuang, Chih-Hung Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2015
Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinomaJeng-Sen Tseng, Chih-Liang Wang, Tsung-Ying Yang, et al.
Oncotarget|July 8, 2016
The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790MJeng-Sen Tseng, Kang-Yi Su, Tsung-Ying Yang, et al.
Scientific Reports|May 1, 2021
Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitorsPo-Hsin Lee, Tsung-Ying Yang, Kun-Chieh Chen, et al.
International Journal of Antimicrobial Agents|January 11, 2020
Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniaeTsung-Ying Yang, Sheng-Fan Wang, Jun-En Lin, et al.
Oncology|September 7, 2020
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI TreatmentJeng-Sen Tseng, Kuo-Hsuan Hsu, Zhe-Rong Zheng, et al.
Cell Death & Disease|April 25, 2020
RAGE acts as an oncogenic role and promotes the metastasis of human lung cancerMei-Chih Chen, Kun-Chieh Chen, Gee-Chen Chang, et al.
Scientific Reports|June 13, 2022
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patientsKuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, et al.
Targeted Oncology|April 23, 2022
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in TaiwanYen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, et al.
Scientific Reports|June 9, 2021
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790MYen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, et al.
Pageof 18